# ORIC earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ORIC) · [Earnings tab](https://www.lopjlb.com/stock/ORIC?tab=earnings)

Updated: 2026-11-16T06:52:57

Quarters analyzed: 1

## Cross-quarter narrative

In the 2021 Q4 earnings call, ORIC announced the discontinuation of ORIC-101 following insufficient efficacy in two combination studies. This decision freed resources and extended the company's cash runway to the second half of 2024. Management highlighted advancement of three clinical programs — ORIC-533, ORIC-114, and a third unnamed program — with data readouts expected in the first half of 2023. The company remains pre-revenue, with demand visibility tied to clinical progress and partner interest. Cost structure is focused on R&D, and capital allocation is directed toward the three ongoing programs. Management tone was slightly positive (0.20), QA pressure moderate (0.40), guidance was maintained, and uncertainty was elevated (0.60). No specific fears, delays, or milestone slippages were disclosed.

## Latest CallCard · Q4

ORIC discontinues ORIC-101 after insufficient efficacy in two combination studies; advances three clinical programs with data expected 1H2023; cash runway extended to 2H2024.

**Guidance:** maintained — Cash runway extended from 1H2024 to 2H2024 assuming advancement of all pipeline programs; no formal revenue or expense guidance provided.

**Tone:** mgmt 0.2 · Q&A pressure 0.4 · divergence 0.1

Management acknowledges disappointment but emphasizes scientific rigor, efficient decision-making, and highlights robust pipeline with three INDs filed and cash runway extension.

### Demand visibility

No commercial products; demand visibility tied to clinical progress and partner interest.

Analysts inquired about partnership discussions for ORIC-533 and enrollment for CD73; management indicates active partner conversations but no specific guidance.

### Margins / costs

Pre-revenue biotech; cost structure focused on R&D; cash runway extended due to ORIC-101 discontinuation.

Discontinuation of ORIC-101 reduces R&D spend, extending cash runway to 2H2024; no margin discussion.

### Capital allocation

Capital allocated to advancing three clinical programs (ORIC-533, ORIC-114, ORIC

## Quarter one-liners

- **2021 Q4:** ORIC discontinues ORIC-101 after insufficient efficacy in two combination studies; advances three clinical programs with data expected 1H2023; cash runway extended to 2H2024.

## Theme arcs

- **Clinical pipeline prioritization** (new): ORIC-101 discontinued; three programs advanced with 1H2023 data catalysts
- **Cash runway management** (new): Runway extended to 2H2024 due to ORIC-101 discontinuation
- **Pre-revenue commercial readiness** (new): No commercial products; demand tied to clinical progress and partner interest
- **Program discontinuation** (new): ORIC-101 halted after insufficient efficacy in two combination studies

## Guidance path

2021 Q4:maintained

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ORIC`
